HIV Maturation Inhibitor Targeting Gag-Pol Dimerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatment options lack agents that effectively target the maturation phase of the HIV-1 infection cycle, specifically blocking the dimerization of Gag-pol to prevent the activation of protease, leaving the virus in an immature state.
Innovation Solution
A compound of formula (I) is administered to inhibit or prevent the maturation of immature HIV to a mature form by targeting the dimerization of Gag-pol, which can be used alone or in combination with other therapeutic agents to treat HIV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protease inhibitors are used to inhibit HIV-1 protease after activation, then protease activity is blocked, but the virus can still complete maturation and protease activation occurs
Solution Approach 1:
The compound blocks Gag-pol dimerization before protease activation occurs, preventing the protease from ever becoming active. This preliminary intervention stops the maturation process at an earlier stage than protease inhibitors, which only block activity after activation has already occurred.
Solution Approach 2:
The invention extracts and targets a specific critical step in the maturation pathway (Gag-pol dimerization) that is necessary for subsequent protease activation. By removing this essential intermediate step, the virus cannot progress to the protease activation stage that protease inhibitors would otherwise block.
2Adaptability or versatility
If agents target the maturation phase by blocking Gag-pol dimerization, then protease activation is prevented, but few antiviral agents currently block this specific step
Solution Approach 1:
The compound changes the chemical parameters of the interaction between Gag-pol proteins by forming a covalent bond with a cysteine residue, thereby preventing the dimerization interface from functioning. This chemical modification approach provides a novel mechanism not available in existing antiviral agents.
Solution Approach 2:
The compound acts as an intermediary molecule that binds to Gag-pol and physically prevents the dimerization interaction. This intermediary blocks the direct protein-protein interaction required for maturation without requiring to inhibit protease activity directly.
3Reliability
If combinations of two or more agents from different classes are administered, then coverage of different replication pathways is achieved, but treatment complexity increases
Solution Approach 1:
The compound provides a universal blocking mechanism at the maturation stage that is independent of other antiviral targets. By acting on Gag-pol dimerization rather than protease activity, reverse transcriptase, or integration, it offers a multi-functional approach that can be combined with various other agent classes without increasing mechanistic complexity.
Data Source
AI summary
Disclosed is a compound of formula (I): for treating or preventing a human immunodeficiency virus (HIV) infection in a mammal, for inhibiting or preventing maturation of an immature human immunodeficiency virus (HIV) to a mature HIV, and for preventing or inhibiting a human immunodeficiency virus (HIV) infection in a mammal having at least one HIV viral particle on a surface thereof.